Patents Assigned to The Board of Regents of the University of Texas Systems
  • Publication number: 20250034091
    Abstract: Compositions for treating a neurological disorder comprise lanosterol synthase inhibitors.
    Type: Application
    Filed: September 20, 2024
    Publication date: January 30, 2025
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Deepak Nijhawan, Huayu Wang, Christopher Carroll, Thu Nguyen
  • Patent number: 12207834
    Abstract: The disclosure provides a surgical apparatus comprising: a steerable member that is bendable and comprises a plurality of bending segments with channels therein; and a plurality of bending actuation wires that are arranged to pass through the steerable member and cause the steerable member to bend, the steerable member comprising at least one outwardly opening lumen through which the bending actuation wires pass.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: January 28, 2025
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Daniel H. Kim, Dong Suk Shin, Taeho Jang, Yong Man Park
  • Patent number: 12209240
    Abstract: Provided are antisense oligomers targeted against bacterial mRNAs and other macromolecules associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: January 28, 2025
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: David Greenberg, Bruce L. Geller
  • Patent number: 12201684
    Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: January 21, 2025
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Burton Dickey, Michael Tuvim, Scott Evans
  • Patent number: 12201700
    Abstract: The present invention provides targeting probe, imaging probes, and probes for use as a medicament to treat damaged cartilage, where the probe targets injured tissue and can then be imaged and/or release agents to trigger the migration of surrounding chondrocytes from healthy tissue to injured tissue and/or recruit synovial stem cells.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 21, 2025
    Assignees: Board of Regents, The University of Texas System
    Inventors: Liping Tang, Jun Zhou, Joseph Borrelli
  • Patent number: 12202895
    Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: January 21, 2025
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, IMMUNE-ONC THERAPEUTICS, INC.
    Inventors: Zhiqiang An, Chengcheng Zhang, Ningyan Zhang, Xun Gui, Mi Deng, Tao Huang, Qiang Liu, X. Charlene Liao
  • Patent number: 12202877
    Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: January 21, 2025
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian Yee, Ke Pan
  • Patent number: 12203138
    Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: January 21, 2025
    Assignees: Board of Regents, The University of Texas System, Duke University, Case Western Reserve, The Regents of the University of California
    Inventors: Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Simon G. Gregory, Farren B. S. Briggs, Lisa F. Barcellos, Shelton S. Bradrick, Irina Evsyukova, Dennis C. Ko
  • Patent number: 12203107
    Abstract: A crystal structure of a Non-LTR-retroelement reverse transcriptase and methods of using the same to identify enzymes with improved activity are provided. Mutant reverse transcriptase enzymes and methods of using the same are also provided.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: January 21, 2025
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer L. Stamos, Alfred M. Lentzsch, Seung Kuk Park, Georg Mohr, Alan M. Lambowitz
  • Publication number: 20250019465
    Abstract: Provided herein are single domain antibodies (sdAbs) having a specific affinity for a rare heparan sulfate moiety which can be used to disrupt DC-HIL function to reduce and prevent cancer progression and metastasis. Compositions and methods of use thereof are also provided for use of these sdAbs to treat cancer and cancer metastasis in a subject in need thereof.
    Type: Application
    Filed: November 14, 2022
    Publication date: January 16, 2025
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Kiyoshi ARIIZUMI, Jin-Sung CHUNG, Ponciano D. CRUZ, Jr.
  • Publication number: 20250017926
    Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide, eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 31, 2024
    Publication date: January 16, 2025
    Applicant: Board of Regents, The University of Texas System
    Inventors: Greg Dussor, Jacob E. Lackovic
  • Patent number: 12195804
    Abstract: The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K/mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K/mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K/mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: January 14, 2025
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Faye Johnson, Mitchell Jay Frederick
  • Patent number: 12193786
    Abstract: A hyperspectral imaging system can include a first hyperspectral imaging camera that is configured to provide first hyperspectral image data of an object in a first field of view. A second hyperspectral imaging camera can be separated from the first hyperspectral imaging camera, where the second hyperspectral imaging camera is configured to provide second hyperspectral image data of the object in a second field of view. A processor circuit can be operatively coupled to the first and second hyperspectral imaging cameras, where the processor circuit configured to combine the first and second hyperspectral image data to generate a hypercube of data for the object comprising spectral data included in the first and second hyperspectral image data.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: January 14, 2025
    Assignee: Boards of Regents, The University of Texas System
    Inventor: Baowei Fei
  • Patent number: 12194319
    Abstract: Provided herein are noninvasive stimulation methods and apparatus for the treatment of injury to tissues using a novel pulsed laser system that combines the benefits of near-infrared laser light and optoacoustic waves. In certain embodiments, short, high-energy laser light pulses generate low intensity ultrasound waves that travel deep into brain tissues to stimulate neural function and treat neurological dysfunctions. In certain embodiments, a patient interface is provided wherein optoacoustic waves are produced by a plurality of optical absorbers overlying all of a plurality of optical fibers while in other embodiments optoacoustic waves are generated both inside the tissue and outside the tissue via a plurality of optical absorbers overlying some but not all of the optical fibers thus enabling an option of varying proportions of optoacoustic waves generated inside and outside of tissue.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 14, 2025
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rinat O. Esenaliev, Maria-Adelaide Micci, Donald S. Prough
  • Patent number: 12193821
    Abstract: Manufacturing a neural interface device. Forming a neural interface probe of an implantable microelectrode body. PECVD a first amorphous silicon carbide insulation layer, forming a thin film metal trace and interface pad on the first layer, the pad on a portion of the trace. PECVD a second amorphous silicon carbide insulation layer on the first layer and covering the trace and the pad. Forming an opening in the second layer to expose the pad to an ambient environment. Patterning the first and second layers to define the neural interface probe. The probe has a rectangular cuboid shape, a cross-sectional area perpendicularly transverse to a long axis length of the probe and through any perpendicularly transverse cross-section along the long axis length is less than about 50 microns. The layers are the principle material of construction of the probe.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 14, 2025
    Assignees: Board of Regents, The University of Texas System, Trustees of Boston University
    Inventors: Timothy James Gardner, Stuart F. Cogan
  • Patent number: 12195803
    Abstract: Provided herein are methods and materials for detecting and/or treating subject (e.g. a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g. a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: January 14, 2025
    Assignees: The Johns Hopkins University, Board of Regents, The University of Texas System, The Research Foundation for The State University of New York
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Joshua Cohen, Nickolas Papadopoulos, Anne Marie Lennon, Cristian Tomasetti, Yuxuan Wang, Georges Jabboure Netto, Rachel Karchin, Christopher Douville, Samir Hanash, Simeon Springer, Arthur P. Grollman, Kathleen Dickman
  • Patent number: 12193770
    Abstract: An instrument cart configured to position an instrument controller at a desired location and attitude pitch with respect to an incision location of a patient includes a base, a lift member moveable with respect to the base, a first planar translation member connected to the lift member and arcuately moveable with respect thereto, a second planar translation member connected to the first planar translation member and arcuately moveable with respect thereto, a third planar translation member connected to the second planar translation member and arcuately moveable with respect thereto, an arcuate slide base connected to the third planar translation member and moveable with respect thereto and an arcuate slide coupled to the arcuate slide base, and moveable with respect thereto; and an instrument controller coupling connected to the arcuate slide member, the instrument controller connected thereto and movable with respect thereto.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 14, 2025
    Assignees: Board Of Regents Of The University Of Texas System, ColubrisMX, Inc
    Inventors: Daniel H. Kim, Dong Suk Shin, Taeho Jang, Yongman Park, Jeihan Lee, Kihoon Nam, Yongchul Shin
  • Patent number: 12198352
    Abstract: Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.
    Type: Grant
    Filed: August 14, 2023
    Date of Patent: January 14, 2025
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Darin T Okuda, Braeden D Newton
  • Patent number: 12194059
    Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 14, 2025
    Assignee: Board of Regents, The University of Texas System
    Inventor: Jian Yang
  • Patent number: 12195206
    Abstract: An electrospray thruster with integrated propellant storage directly embedded into small satellite structural elements integrates the volume of the thruster into the volume of the rail.
    Type: Grant
    Filed: January 4, 2023
    Date of Patent: January 14, 2025
    Assignee: Board of Regents, The University of Texas System
    Inventor: Amelia Diane Greig